BRAVE program to reduce violence risk in early psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests BRAVE, a brief, manualized cognitive-behavioral therapy intervention designed to address modifiable violence-related factors in early psychosis. Using a stepped-wedge design, all participants start with treatment as usual and are sequentially transitioned to BRAVE while continuing standard care. Assessments are conducted throughout the treatment-as-usual, BRAVE, and follow-up periods, with collateral informants contributing data. Primary goals are to determine feasibility and acceptability, with secondary aims examining changes in violence-related behaviors and related outcomes to inform future larger studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Young adults aged 16-30 years
* Diagnosis of early psychosis
* Currently receiving outpatient care through an early psychosis clinic
* Psychiatrically stable and deemed appropriate for participation by a treating clinician
* Able and willing to provide informed consent

Exclusion Criteria:

* Unable to provide informed consent
* Not fluent in English
* History of antisocial behavior, as assessed at baseline
* Immediate risk requiring a higher level of care

Where it's running

• Howard University Hospital
  Washington D.C., District of Columbia, United States Recruiting
• Howard University Hospital
  Washington D.C., District of Columbia, United States Not yet recruiting

Study contacts

• Study coordinator: Stephanie Rolin, MD MPH
• Email: stephanie.rolin@howard.edu
• Phone: (202) 865-6100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Digital strategies to improve help-seeking for youth at risk of psychosis

  This study is testing new digital tools to help young people aged 12-29 who are at risk for psychosis find the support they need and start treatment faster.

  Recruiting Columbia University · New York, New York · NCT06774430

• Digital tools to help youth seek care sooner when at risk for psychosis

  This project will test personalized digital messages and online strategies to help people ages 12–29 who screen positive for psychosis risk find and start local care sooner.

  Recruiting Columbia University · New York, New York · NCT06774417

• Understanding early psychosis and its biological markers

  This study is trying to find out more about early signs of psychotic disorders like schizophrenia and bipolar disorder by looking at brain scans and other health data from around 320 participants over a year.

  Recruiting at 6 sites Beth Israel Deaconess Medical Center · Hartford, Connecticut and 5 other locations · NCT06740383

• Using Cannabidiol to Treat Early Psychosis

  This study is testing if adding Cannabidiol (CBD) to the usual treatment can help young people and adults with early psychosis feel better and improve their symptoms.

  Recruiting at 2 sites Phase 3 University of California, San Diego · La Jolla, California and 1 other locations · NCT04411225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.